Compare THCH & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THCH | NNVC |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 35.2M |
| IPO Year | 2021 | 2008 |
| Metric | THCH | NNVC |
|---|---|---|
| Price | $1.45 | $1.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 12.4K | ★ 169.6K |
| Earning Date | 12-08-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.85 |
| 52 Week High | $2.73 | $2.03 |
| Indicator | THCH | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 50.00 |
| Support Level | $1.10 | $1.23 |
| Resistance Level | $1.61 | $1.49 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 75.47 | 34.78 |
TH International Ltd is the exclusive master franchisee in China for Tim Hortons, a world-wide coffee and bakery shop brand. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under a single reportable segment, Tim Hortons. The company's revenue is derived from sales of food, beverages, and packaged products by company-owned and operated stores, franchise fees, and revenue from other franchise support activities. Its geographic revenue is derived from operations in the PRC.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.